Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo.

Publication

Citation: Thoma G, Beerli C, Bigaud M, Bruns C, Cooke NG, Streiff MB, Zerwes HG.: Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Bioorg Med Chem Lett, Volume 18 (6), 2008
Authors: Beerli C, Bigaud M, Bruns C, Cooke NG, Streiff MB, Thoma G, Zerwes HG.
Journal: Bioorg Med Chem Lett
Year: 2008
DOI: 10.1016/j.bmcl.2008.01.108
PubMed: 18267361
Machine-readable: REST API RDF

Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. | MolMeDB